ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,127.79
1.26%
Dow Jones
38,675.68
1.18%
US Dollar vs MXN
16.9724
0.00%
Brent Oil
82.765
0.00%
Bitcoin
64,272.76
0.60%
Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Harpoon Therapeutics Inc (HARP)

  7. Harpoon Therapeutics Inc (HARP) Noticias

HARP Harpoon Therapeutics Inc

23.01
0.00 (0.00%)
02 May 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Harpoon Therapeutics Inc HARP NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
Upgrade Icon
0.00 0.00% 23.01 19:00:00
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
23.01 23.01
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
11/3/202416:22EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11/3/202408:55EDGAR2Form POS AM - Post-Effective amendments for registration..
11/3/202408:46EDGAR2Form S-8 POS - Securities to be offered to employees in..
11/3/202407:47EDGAR2Form 8-K - Current report
08/3/202415:04EDGAR2Form 8-K - Current report
28/2/202406:37EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
28/2/202406:34EDGAR2Form 8-K - Current report
22/2/202407:32EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
22/2/202407:31EDGAR2Form 8-K - Current report
08/2/202406:00EDGAR2Form DEFM14A - Definitive proxy statement relating to merger..
06/2/202415:15EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
29/1/202415:52EDGAR2Form PREM14A - Preliminary proxy statements relating to..
29/1/202415:28EDGAR2Form 8-K - Current report
10/1/202414:07PRNUSKuehn Law Encourages AMAM, HARP, AXNX, and CPE Investors to..
09/1/202405:12IHMARKETNEWSWall Street Highlights: HPE and Juniper Networks in..
08/1/202416:20EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
08/1/202416:16EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
08/1/202407:04EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
08/1/202407:01EDGAR2Form 8-K - Current report
08/1/202406:30BWMerck to Acquire Harpoon Therapeutics, Further Diversifying..
05/1/202416:04EDGAR2Form S-8 - Securities to be offered to employees in employee..
26/12/202306:30GLOBEHarpoon Therapeutics Strengthens Leadership Team
22/12/202315:06EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
19/12/202323:15EDGAR2Form EFFECT - Notice of Effectiveness
19/12/202306:30GLOBEHarpoon Therapeutics Abstract for HPN328 Accepted for Rapid..
11/12/202319:15GLOBEHarpoon Therapeutics Presents HPN217 Phase 1 Clinical Data..
08/12/202315:08EDGAR2Form S-3 - Registration statement under Securities Act of..
28/11/202315:23EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/11/202315:14EDGAR2Form 8-K - Current report
24/11/202313:06EDGAR2Form 8-K - Current report
24/11/202313:01EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
09/11/202315:28EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/11/202315:11EDGAR2Form 8-K - Current report
09/11/202315:01GLOBEHarpoon Therapeutics Reports Third Quarter 2023 Financial..
03/11/202315:05EDGAR2Form SC 13G - Statement of acquisition of beneficial..
02/11/202308:15GLOBEHarpoon Therapeutics Abstract for HPN217 Accepted for..
26/10/202316:00EDGAR2Form SC 13G - Statement of acquisition of beneficial..
23/10/202307:00EDGAR2Form 8-K - Current report
23/10/202306:17GLOBEHarpoon Therapeutics Announces Up to $150 Million Private..
21/10/202310:31GLOBEHarpoon Therapeutics Announces Updated Interim Tolerability..
16/10/202315:05GLOBEHarpoon Therapeutics to Host Webcast Reviewing HPN328..
09/10/202315:17GLOBEHarpoon Therapeutics to Present Interim Tolerability and..
02/10/202316:34EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/9/202302:00GLOBEHarpoon Therapeutics Presents HPN217 Interim Phase 1 Data at..
15/9/202306:15GLOBEHarpoon Therapeutics Announces First Patients with Small..
13/9/202316:12DJNHarpoon Shares Drop 7.3% as AbbVie Declines License Option
13/9/202315:55DJNHarpoon Therapeutics Says AbbVie Declines to Exercise..
13/9/202315:15EDGAR2Form 8-K - Current report
13/9/202315:05GLOBEHarpoon Therapeutics Provides an Update on the HPN217..
06/9/202306:30GLOBEHarpoon Therapeutics Abstract for HPN217 Accepted for Poster..

Su Consulta Reciente

NASDAQ
HARP
Harpoon Therapeutics
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados